5922-56-5

Basic information

• Product Name: 4-METHOXY-3-PROPOXYBENZALDEHYDE
• Synonyms: Benzaldehyde, 4-methoxy-3-propoxy-
• CAS NO: 5922-56-5
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.23
• Mol File: 5922-56-5.mol

Chemical Properties

• Boiling Point: 637.4°C at 760 mmHg
• Flash Point: 339.3°C
• Appearance: /
• Density: 1.392g/cm³
• Vapor Pressure: 3.82E-16mmHg at 25°C
• Refractive Index: 1.597
• CAS DataBase Reference: 4-METHOXY-3-PROPOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-3-PROPOXYBENZALDEHYDE(5922-56-5)
• EPA Substance Registry System: 4-METHOXY-3-PROPOXYBENZALDEHYDE(5922-56-5)

Safety Data

• Hazardous Substances Data: 5922-56-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C18H20ClNO5S2/c1-13-11-17(26(21,22)16-5-3-15(19)4-6-16)14(2)18(12-13)27(23,24)20-7-9-25-10-8-20/h3-6,11-12H,7-10H2,1-2H3

Upstream product

• 621-59-0 isovanillin 
• 106-94-5 propyl bromide 
• 148433-01-6 3-(3-bromopropoxy)-4-methoxybenzaldehyde 
• 107-08-4 1-iodo-propane 
• 90-05-1 2-methoxy-phenol 
• 29515-39-7 1-methoxy-2-n-propoxybenzene 
• 93-61-8 N-methyl-N-phenylformamide 
• 110943-74-3 4-hydroxy-3-propoxybenzaldehyde 
• 77-78-1 dimethyl sulfate 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 

Downstream Products

• 117666-85-0 (E)-3-(4-Methoxy-3-propoxy-phenyl)-thioacrylic acid O-ethyl ester 
• 5922-57-6 4-Methoxy-3-propoxy-benzoic acid 
• 99661-61-7 (E)-3-(4-Methoxy-3-propoxy-phenyl)-thioacrylamide 
• 1007836-31-8 6-[1-(4-methoxy-3-propoxy-benzyl)-piperidin-4-ylamino]-4-trifluoromethyl-nicotinic acid methyl ester 
• 99661-77-5 {2-[(E)-2-(4-Methoxy-3-propoxy-phenyl)-vinyl]-thiazol-4-yl}-acetic acid 
• 144036-21-5 4-Methoxy-3-propoxy-benzoyl chloride 
• 261359-03-9 3-(propyloxy)-4-methoxybenzyl alcohol 
• 1369421-38-4 1-(4-methoxy-3-propoxyphenyl)-2-methylpropan-1-ol 
• 621-59-0 isovanillin 

Relevant articles and documents

Understanding the cytotoxic effects of new isovanillin derivatives through phospholipid Langmuir monolayers

Twenty-one isovanillin derivatives were prepared in order to evaluate their cytotoxic properties against the cancer cell lines B16F10-Nex2, HL-60, MCF-7, A2058 and HeLa. Among them, seven derivatives exhibited cytotoxic activity. We observed that for obtaining smaller IC50 values and for increasing the index of selectivity, two structural features are very important when compared with isovanillin (1); a hydroxymethyl group at C-1 and the replacement of the hydroxyl group at C-3 by different alkyl groups. As the lipophilicity of the compounds was changed, we decided to investigate the interaction of the cytotoxic isovallinin derivatives on cell membrane models through Langmuir monolayers by employing the lipids DPPC (1,2-diplamitoyl-sn-glycero-3-phosphocoline) and DPPS (1,2-diplamitoyl-sn-glycero-3-phosphoserine). The structural changes on the scaffold of the compounds modulated the interaction with the phospholipids at the air-water interface. These results were very important to understand the biophysical aspects related to the interaction of the cytotoxic compounds with the cancer cell membranes.

PERFUME SYSTEMS

The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

Practical Ligand-Free Copper-Catalysed Short-Chain Alkoxylation of Unactivated Aryl Bromides

An efficient and practical short-chain alkoxylation of unactivated aryl bromides has been developed with special attention focussed on the applicability of the reaction. Sodium alkoxide is used as the nucleophile, and the corresponding alcohol as the solvent. The reaction requires neither precious metals nor organic ligands. It uses a catalytic system consisting of copper(I) bromide as a catalyst, the corresponding alkyl formate as a noncontaminating cocatalyst, and lithium chloride as an additive. A wide range of substrates and test cases highlight the synthetic utility of the approach. Considering the commercial accessibility and affordability of the feedstocks, this protocol shows promise as a new alternative for the sustainable preparation of aryl alkyl ethers.

Concurrent synthesis of vanillin and isovanillin

A method for concurrent synthesis of vanillin and isovanillin has been developed by a nonregioselective Vilsmeier-Haack reaction of O-alkyl guaiacols. O-Alkylation of guaiacol provided the corresponding O-alkyl guaiacol (1), which was then formylated with N-methylformanilide/phosphorus oxychloride to give a mixture of 4-alkoxy-3-methoxy-benzaldehyde (2) and 3-alkoxy-4- methoxybenzaldehyde (3). Finally, the obtained mixture underwent a selective dealkylation by anhydrous aluminium trichloride, while leaving methyl groups intact to simultaneously achieve the significant fine chemicals vanillin and isovanillin.

PYRIMIDINE AND QUINAZOLINE DERIVATIVES

This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES

This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES

This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES

This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.